137 related articles for article (PubMed ID: 30921251)
1. Can 18F-FDG PET/CT diagnose malignant change in benign chondroid tumors?
Purandare NC; Puranik A; Shah S; Agrawal A; Puri A; Gulia A; Nayak P; Rekhi B; Rangarajan V
Nucl Med Commun; 2019 Jun; 40(6):645-651. PubMed ID: 30921251
[TBL] [Abstract][Full Text] [Related]
2. Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation?
Purandare NC; Puranik A; Shah S; Agrawal A; Gupta T; Moiyadi A; Shetty P; Shridhar E; Jalali R; Rangarajan V
Nucl Med Commun; 2017 Dec; 38(12):1109-1116. PubMed ID: 28922334
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
5. Differentiation and diagnosis of benign and malignant testicular lesions using 18F-FDG PET/CT.
Shao D; Gao Q; Tian XW; Wang SY; Liang CH; Wang SX
Eur J Radiol; 2017 Aug; 93():114-120. PubMed ID: 28668404
[TBL] [Abstract][Full Text] [Related]
6. F-18 FDG PET differentiation of benign from malignant chondroid neoplasms: a systematic review of the literature.
Subhawong TK; Winn A; Shemesh SS; Pretell-Mazzini J
Skeletal Radiol; 2017 Sep; 46(9):1233-1239. PubMed ID: 28608242
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
Chirindel A; Chaudhry M; Blakeley JO; Wahl R
J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma.
Kim BH; Kim SJ; Kim H; Jeon YK; Kim SS; Kim IJ; Kim YK
Nucl Med Commun; 2013 Sep; 34(9):868-76. PubMed ID: 23797273
[TBL] [Abstract][Full Text] [Related]
9. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
[TBL] [Abstract][Full Text] [Related]
10. Integrated PET/CT in evaluating sarcomatous transformation in osteochondromas.
Purandare NC; Rangarajan V; Agarwal M; Sharma AR; Shah S; Arora A; Parasar DS
Clin Nucl Med; 2009 Jun; 34(6):350-4. PubMed ID: 19487843
[TBL] [Abstract][Full Text] [Related]
11. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of
Altinmakas E; Hobbs BP; Ye H; Grubbs EG; Perrier ND; Prieto VG; Lee JE; Ng CS
Abdom Radiol (NY); 2017 Feb; 42(2):577-584. PubMed ID: 27665482
[TBL] [Abstract][Full Text] [Related]
13. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
14. Value of
Xi XY; Gao W; Gong JN; Guo XJ; Wu JY; Yang YH; Yang MF
Int J Cardiovasc Imaging; 2019 Jul; 35(7):1395-1403. PubMed ID: 30747369
[TBL] [Abstract][Full Text] [Related]
15.
Annovazzi A; Anelli V; Zoccali C; Rumi N; Persichetti A; Novello M; Sciuto R; Bertoni F; Ferraresi V; Biagini R
Ann Nucl Med; 2019 Nov; 33(11):813-821. PubMed ID: 31396797
[TBL] [Abstract][Full Text] [Related]
16. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
17. A stepwise approach using metabolic volume and SUVmax to differentiate malignancy and dysplasia from benign colonic uptakes on 18F-FDG PET/CT.
Oh JR; Min JJ; Song HC; Chong A; Kim GE; Choi C; Seo JH; Bom HS
Clin Nucl Med; 2012 Jun; 37(6):e134-40. PubMed ID: 22614211
[TBL] [Abstract][Full Text] [Related]
18. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.
Magometschnigg HF; Baltzer PA; Fueger B; Helbich TH; Karanikas G; Dubsky P; Rudas M; Weber M; Pinker K
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1656-1665. PubMed ID: 26121928
[TBL] [Abstract][Full Text] [Related]
20. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
